How COVID antibody cocktails could help protect unvaccinated people
Regeneron's antibody cocktail could effectively provide "immediate protection to unvaccinated people," the company said Monday.
Regeneron announced that in a phase 3 trial, its monoclonal antibody cocktail protected against COVID-19 among people who were living with someone infected with the coronavirus, The New York Times reports.
This trial consisted of 1,505 people who lived in the same household as a person who tested positive for COVID-19 within the previous four days, and the antibody cocktail reduced the risk of symptomatic COVID-19 by 81 percent. Regeneron says it will ask the FDA to expand the emergency use authorization given to the antibody cocktail, which is now used for high-risk people infected with COVID-19.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"These antibodies may be particularly useful in individuals who are not yet vaccinated, and may also have potential in those who are immunosuppressed and may not respond well to vaccines," Dan Barouch, the trial's co-principal investigator, said.
Regeneron Chief Scientific Officer George Yancopoulos also said the antibody cocktail "may help provide immediate protection to unvaccinated people who are exposed to the virus." This study was the newest evidence suggesting that drugs of this kind "not only prevent the worst outcomes of the disease when given early enough, but also help prevent people from getting sick in the first place," the Times wrote, while The Wall Street Journal noted the Regeneron drug could "provide temporary stopgap protection as people await vaccines."
Myron Cohen, one of the lead investigators of the study, also pointed out to Stat News that it's a "really, really big deal" that the Regeneron study administered the antibody drug via an injection, as needing to start an IV to use such antibody drugs has "unequivocally" been a barrier.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Passenger: 'pleasingly off-kilter' ITV crime drama
The Week Recommends There's 'plenty to be feared' in this British murder mystery set in a quiet northern town
By Adrienne Wyper, The Week UK Published
-
Crossword: March 27, 2024
The Week's daily crossword
By The Week Staff Published
-
Sudoku hard: March 27, 2024
The Week's daily hard sudoku puzzle
By The Week Staff Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published